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Abstract
NUT carcinoma is an aggressive carcinoma with an overall poor survival outcome. The mediastinum and head and neck area, 
especially the sinonasal region, are among the common sites of disease. Histopathological diagnosis of NUT carcinoma is 
often very challenging due to its overlapping features with other poorly differentiated carcinomas. We report a case of NUT 
carcinoma arising from the parotid gland of a young female patient. Primary NUT carcinoma of salivary gland is very rare, 
with only 15 such cases reported in the literature to date. Our case highlights the diagnostic challenges associated with such 
lesions.
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Introduction
NUT carcinoma is a rare, poorly differentiated carcinoma 
characterised by a genomic rearrangement of the nuclear 
protein of testis (NUT) gene, with BRD4-NUT being the 
most common fusion variant. It generally arises from the 
mediastinum, but numerous cases involving the head and 
neck, mainly from the sinonasal region, have been reported 
[1–5]. NUT carcinoma has a poor prognosis, with a mean 
survival of less than 12 months from diagnosis. People of all 
ages are equally affected, with no gender predilection [6–9]. 
Patients normally present with advanced lesions, typically of 
a rapidly expanding mass at the site involved [6]. There are 
no effective treatment regimens available to date.
Case History
A 34-year-old 6-week post-partum female with no signifi-
cant medical history presented with a short-term history of 
a left parotid lump. Magnetic resonance imaging (MRI) and 
positron emission tomography (PET) imaging identified a 
solitary well-defined, 38 mm lesion within the left parotid 
gland (Fig. 1). The initial core biopsy was suggestive of a 
high-grade neuroendocrine carcinoma. Following this, the 
patient underwent a radical parotidectomy and ipsilateral 
selective neck dissection. The histology of the left parot-
idectomy was reported locally as a high-grade salivary gland 
neoplasm, possibly high-grade mucoepidermoid carcinoma. 
There was evidence of perineural invasion as well as meta-
static deposits in two lymph nodes. The patient underwent 
adjuvant radiotherapy; however, a new lump appeared one 
month later, at the left parotidectomy surgical site. MRI and 
Computerized tomography (CT) imaging demonstrated a 
recurrent lesion in the left parotid region, accompanied by 
widespread metastatic disease in the spine and skull base 
(Fig. 1).
Following this recurrence, the pathology was reviewed 
at a tertiary specialist oral and maxillofacial pathology 
department. Histology showed a multilobular and widely 
infiltrative neoplasm largely with a ‘small round blue cell’ 
morphology, exhibiting largely cohesive sheets of undiffer-
entiated cells (Fig. 2). The cells demonstrated significant 
nuclear and cellular pleomorphism, with prominent nucleoli 
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with focal cytoplasmic clearing. This was accompanied by 
extensive necrosis and frequent mitoses. Focally, there was 
evidence of an abrupt squamous appearance (Fig. 2). Extrag-
landular invasion was present, with tumour islands extending 
into the surrounding skeletal muscle, in addition to extensive 
perineural invasion and lymphovascular invasion. There was 
metastatic disease in one periparotid lymph node and a facial 
node, with extranodal extension in the latter.
Immunohistochemistry (IHC) showed strong and dif-
fuse expression of p16, p63 and p40, whereas more vari-
able staining was observed for AE1/AE3, CK5/6, Cam 5.2 
and CD56. CK7 expression was only seen in the squamous/
epithelial islands with a large proportion of the neoplastic 
population being negative. There was focal expression of 
synaptophysin, whereas CK14, CK20, chromogranin, CD45, 
CD99, S100, SMA, TTF1, AR, ER, HER-2 and EBER ISH 
were negative. Fluorescence in-situ hybridization (FISH) 
with MAML2 break-apart probe) showed no evidence of 
MAML2 rearrangement.
The diagnosis of NUT carcinoma was confirmed follow-
ing strong and diffuse nuclear staining for NUT throughout 
the tumoral population (Fig. 3). Three-weekly Pembroli-
zumab immunotherapy was administered alongside pal-
liative radiotherapy to the head and neck region and spine. 
The patient died of progressive and widespread metastatic 
disease from the original salivary lesion within six months 
of diagnosis.
Discussion
NUT carcinoma is considered by some authors to represent 
a subtype of squamous cell carcinoma (SCC). However, the 
BRD4-NUT fusion and the lack of SCC molecular signa-
ture in NUT carcinoma makes this relationship somewhat 
controversial [2, 10]. NUT carcinoma has overlapping fea-
tures with other poorly differentiated carcinomas, making 
the diagnosis challenging, and extensive IHC and molecular 
testing are often required for definitive diagnosis. Although 
Fig. 1  T2-weighted MRI 
images from left to right: a 
Pre-operative staging image in 
the coronal plane demonstrates 
a well-defined tumour in the 
left parotid gland. b, c Imaging 
one month later demonstrates 
extensive tumour invading into 
the lower neck, mandible and 
skull base in both coronal and 
axial planes
Fig. 2  Representative H&E photomicrographs showing sheets of the 
carcinoma with a small round blue cell appearance. Note the abrupt 
squamous differentiation (a, b) and necrosis (c)
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the number of reported salivary gland origin NUT carcino-
mas is low, it is thought that the prevalence of this disease 
remains under-reported due to misdiagnosis [7, 11–13].
Characteristic histopathological features of NUT 
carcinoma include diffuse sheets of undifferentiated 
oval-to-polygonal cells with prominent nucleoli showing 
eosinophilic-to-clear cytoplasm. This is accompanied by 
necrosis, mitoses and abrupt keratinisation or squamous 
change. Recognizing these features can be helpful to exclude 
some other neoplasms, but these features are not entirely 
diagnostic. NUT carcinomas arising from the salivary glands 
are known to demonstrate a similar immunoprofile to those 
seen in other anatomic sites. Moreover, diagnosis is likely 
to be challenging on core biopsy material, which may not be 
representative of the complete morphology and architecture 
of the neoplasm. The tumour commonly expresses cytokerat-
ins and squamous markers such as p63. The morphology of 
NUT carcinoma can often mimic neuroendocrine carcinoma; 
however, neuroendocrine markers are predominantly nega-
tive, with variable patchy positivity for synaptophysin and 
CD56 being described [8, 10, 14]. This variable expression 
of synaptophysin is a major pitfall, in particular on biopsies.
This case was challenging because the largely undifferen-
tiated morphological appearance was difficult to distinguish 
from a high-grade salivary neoplasm (e.g. neuroendocrine 
carcinoma, high grade MEC, acinic cell carcinoma with 
high-grade transformation, high grade myoepithelial carci-
noma) or a metastatic neoplasm [15, 16]. Salivary gland 
neoplasms that commonly show a clear cell population such 
as mucoepidermoid carcinoma, epithelial-myoepithelial car-
cinoma and myoepithelial carcinoma should be considered 
in the differential diagnosis, although it is uncommon to 
see undifferentiated or very high-grade features in these 
tumours. The presence of ‘squamous’ or ‘epidermoid’ areas 
and clear cells mimicking mucoepidermoid carcinoma can 
be potentially misleading; however, the absence of mucin, 
cytokeratin 7 expression and lack of MAML2 rearrangement 
can help exclude this possibility. Clear cell change can easily 
be mistaken for sebaceous differentiation and can be ruled 
out using androgen receptor. Staining for p16 is positive in 
approximately 40% of NUT carcinoma, which can suggest a 
diagnosis of metastatic oropharyngeal SCC. Crucially, how-
ever, tests for HPV will be negative, and clinical examina-
tion and imaging will not show an oropharyngeal lesion. The 
absence of convincing neuroendocrine marker expression is 
not sufficient for the diagnosis of neuroendocrine carcino-
mas, and the absence of p40 and CD99 positivity helps rule 
out Ewing Sarcoma whereas molecular evidence of EWSR1 
gene rearrangement aids in the exclusion of adamantinoma 
like Ewing sarcoma as these can show consistent cytokeratin 
and p40 expression [10, 11, 17].
Confirming the diagnosis of NUT carcinoma is not pos-
sible without the use of NUT IHC or molecular testing. IHC 
for NUT is performed using commercially available NUT 
(C52B1) antibody, which shows 100% specificity and 87% 
sensitivity. This IHC has been shown to be more sensitive 
than other methods, with diffuse and strong expression in 
more than 50% of tumour nuclei confirming the diagnosis 
Fig. 3  Representative photomicrographs showing IHC staining for 
AE1/AE3 (a), p40 (b), synaptophysin (c) and NUT (d)
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[18]. Alternative methods to confirm NUT rearrangement 
include FISH, reverse transcription-polymerase chain reac-
tion (RT-PCR), cytogenetics or next-generation sequencing-
based approaches. These methods can help determine the 
fusion partner (which can include BRD3, and more rarely 
ZNF532, ZNF592 or CIC) and NSD3 may aid treatment 
involving targeted inhibitors [7, 19–22]. However, aberrant 
NUT protein expression can be seen in germ cell neoplasia 
and must be interpreted cautiously.
NUT carcinoma has an aggressive behaviour, with a 
poor prognosis. Patients normally present with a rapidly 
enlarged mass and lymphadenopathy [6, 18]. Currently, 
there are no gold standards or guidelines for the manage-
ment of NUT carcinoma. Surgical resection of the primary 
tumour remains the mainstay of treatment for local disease 
control. Chemo-radiotherapy can show mixed results, and 
a limited response to chemotherapy has also been reported. 
Post-treatment metastatic disease remains a common com-
plication, despite multimodality treatment approaches being 
adopted in many cases. The development of BET inhibitors 
aimed to inhibit the binding of BRD-NUT and chromatin 
acetylation with histone deacetylase may provide targeted 
therapy and potentially improve prognosis for this highly 
aggressive malignancy [4, 6, 7, 18–20].
Conclusion
Primary NUT carcinoma originating from the salivary 
glands is very rare and a diagnostic challenge. This case 
highlights the importance of considering NUT carcinoma 
in the provisional diagnosis for undifferentiated or poorly 
differentiated salivary gland neoplasms. Immunohistochem-
istry and molecular testing for NUT carcinoma can aid diag-
nosis; however, the lack of widespread accessibility to these 
tests can be a potential barrier to diagnosis and management.
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